国际标准期刊号: 2161-119X

耳鼻喉科:开放获取

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • ICMJE
分享此页面

抽象的

Survivin Gene as a Potential Marker in Premalignant and Malignant Lesions of Oral Cavity

Lingamdenne Paul Emerson and Pallipamu Prakash Babu

In a developing country where most of the people live in rural areas, Oral cancer management is a challenge with most of the cases presenting late. Carcinogenesis is a multistage process involving the activation of oncogenes and the inactivation of tumour suppressor genes. Biomarkers are important in establishing an accurate diagnosis and also can provide prognostic data. Survivin, a member of the inhibitor of apoptosis (IAP) protein family that inhibits caspases and blocks cell death, is highly expressed in most cancers and is associated with a poor clinical outcome. Survivin has consistently been identified by molecular profiling analysis to be associated with high tumour grade cancers, disease survival and recurrence. Polymorphisms in the survivin gene are emerging as powerful tools to study the biology of the disease and have the potential to be used in disease prognosis and diagnosis. The survivin gene polymorphisms have also been reported to influence tumour aggressiveness as well as survival of cancer patients. The differential expression of survivin in cancer cells compared to normal tissues and its role as a nodal protein in a number of cellular pathways make it a high target for different therapeutics. This review focuses on the literature on survivin, its role in cancerous and pre-cancerous lesions of oral cavity. It also gives a snapshot of its use in diagnosis, management and therapeutic management.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。